Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
6 Months : From Apr 2019 to Oct 2019
By Michael Dabaie
Regeneron Pharmaceuticals Inc. (REGN) said results were positive from early-stage data for REGN1979 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
The company said there was a 93% overall response and 71% complete response rates in follicular lymphoma grades 1 to 3a treated with REGN1979 5 mg to 320 mg.
There was a 57% overall response rate in diffuse large B-cell lymphoma treated with REGN1979 80 mg to 160 mg, all of which were complete responses, including two complete responses in four patients whose disease had progressed after CAR-T treatment, the company said.
"We are very encouraged by the continued high response rates observed with REGN1979 in both relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, cancers with typically poor outcomes," said Israel Lowy, head of clinical and translational sciences, oncology at Regeneron.
Write to Michael Dabaie at email@example.com
(END) Dow Jones Newswires
June 14, 2019 07:41 ET (11:41 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.